Revance Therapeutics (RVNC) Misses Q4 EPS by 18c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Revance Releases Fourth Quarter and Full Year 2018 Results
February 26, 2019 4:05 PM EST-Successful 2018: Positive SAKURA 3 topline data, Fosun and Mylan partnerships signed-
-On track to complete BLA submission with U.S. FDA for glabellar lines indication in the first half of 2019-
-Raised approximately $108 million net proceeds from public stock offering on January 22, 2019-
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the fourth quarter and full year ended December 31, 2018 and provided a business update.
Recent Highlights for... More
